Clinical Insight as Due Diligence: What Physicians See Before the Market Does
- Anshul Jain
- 6 days ago
- 2 min read
In traditional investment settings, due diligence is often driven by financial models, market size estimates, and growth projections. While these tools have value, they frequently overlook a critical dimension in healthcare innovation: clinical reality.
Physicians bring a form of insight that cannot be replicated by spreadsheets alone. Their daily exposure to patient outcomes, procedural workflows, and system constraints allows them to identify strengths—and weaknesses—long before they become visible in broader markets.
One key area where physicians add value is workflow assessment. Technologies that appear elegant in theory may introduce inefficiencies, prolong procedures, or complicate postoperative care. Physicians instinctively evaluate whether a product will integrate seamlessly into real clinical environments.
Another dimension is adoption friction. Physicians understand the behavioral and institutional barriers that influence uptake—training requirements, staff acceptance, reimbursement uncertainty, and administrative complexity. These factors often determine whether innovation succeeds or quietly fades.
Physicians also assess clinical durability. Early outcomes may look encouraging, but experienced clinicians consider how a technology performs over time, across diverse patient populations, and in less-than-ideal circumstances.
Importantly, these insights are often surfaced through peer dialogue—case discussions, complication reviews, and informal exchanges at conferences. These conversations form an educational ecosystem where technologies are stress-tested intellectually before they are widely embraced.
Recognizing clinical insight as a legitimate form of due diligence reframes physician education. It emphasizes that thoughtful evaluation is not about enthusiasm or skepticism, but about informed judgment grounded in experience. Financial Education Disclaimer: This article is for educational and informational purposes only and does not constitute financial, investment, or tax advice. The LESS Society is not a licensed fiduciary. Private equity and MedTech investments involve significant risk and illiquidity.
Comments